Skip to main content

and
  1. No Access

    Article

    Antipsychotic potential of the type 1 cannabinoid receptor positive allosteric modulator GAT211: preclinical in vitro and in vivo studies

    Antipsychotics help alleviate the positive symptoms associated with schizophrenia; however, their debilitating side effects have spurred the search for better treatment options. Novel compounds can be screened...

    Dan L. McElroy, Andrew J. Roebuck, Gavin A. Scott, Quentin Greba in Psychopharmacology (2021)

  2. Article

    Cannabinoid Receptor 1 Positive Allosteric Modulators for Posttraumatic Stress Disorder

    Anantha Shekhar, Ganesh A Thakur in Neuropsychopharmacology (2018)

  3. Article

    Erratum: The Novel Cannabinoid CB1 Receptor Neutral Antagonist Am4113 Suppresses Food Intake and Food-Reinforced Behavior but Does not Induce Signs of Nausea in Rats

    Correction to: Neuropsychopharmacology (2008) 33, 946–955; doi:10.1038/sj.npp.1301476; published online 20 June 2007 In this article, the names of two authors were misspelled. The correct names are as follows:...

    Kelly S Sink, Peter J McLaughlin, Jodi Anne T Wood, Cara Brown in Neuropsychopharmacology (2008)

  4. Article

    The Novel Cannabinoid CB1 Receptor Neutral Antagonist AM4113 Suppresses Food Intake and Food-Reinforced Behavior but Does not Induce Signs of Nausea in Rats

    Drugs that interfere with cannabinoid CB1 transmission suppress various food-motivated behaviors, and it has been suggested that such drugs could be useful as appetite suppressants. Biochemical studies indicat...

    Kelly S Sink, Peter J McLaughlin, Jodi Anne T Wood, Cara Brown in Neuropsychopharmacology (2008)